Under Priority Review status, the FDA has accepted Regeneron Pharmaceuticals’ (NASDAQ:REGN) marketing application for REGN-EB3, its triplet therapy for Ebola virus infection. The agency’s action date is October 25.
https://seekingalpha.com/news/3561202-fda-accepts-regeneron-application-for-ebola-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.